Insights on Discovery

  1. At GTC Berlin 2026: Pushing Forward AI In Drug Discovery 10/23/2026

    Protein design models promise faster discovery, yet their value depends on integration with lab data. Scaling that integration takes more than engineering: governance, traceability, and people.

  2. Why AI Alone Will Not Solve Oligonucleotide Discovery 10/21/2026

    Oligonucleotide discovery models are limited less by algorithm design than by the experimental data behind them. Coverage, consistency, and negative results determine whether predictions hold up.

  3. Navigating Data Challenges In RNA Therapeutics: From Complexity To Clarity 10/21/2026

    As RNA discovery scales, higher assay throughput strains analysis and data management. Manual processing and fragmented tools become error-prone, raising questions about standardization.

  4. Designing A Plug-And-Play System To Produce Engineered Extracellular Vesicles 10/16/2026

    Engineered extracellular vesicles can carry proteins, nucleic acids, or small molecules through a modular plasmid and linker approach, paired with a dedicated high-productivity cell line for production.

  5. From LNP Delivery To Functional CAR-T: Rethinking Targeting 10/16/2026

    Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.

  6. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

    Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

  7. Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids 10/13/2026

    Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.

  8. From The Mass Spec Continuum To AI-Enabled Developability Insights 10/9/2026

    Growing modality heterogeneity strains assay-by-assay workflows. Mass spectrometry offers a way to track molecules across development, but its value depends on how the resulting data is handled.

  9. Characterization And Functionality Of SEVs From Different MSC Purification Methods 10/9/2026

    Comparing two purification approaches for mesenchymal stem cell-derived small extracellular vesicles shows where identity, purity, and in vitro bioactivity align and where they diverge.

  10. The Continuing Challenge Of Drug-Induced Liver Injury 9/24/2026

    Recent liver safety concerns highlight the limits of conventional preclinical testing. Human-relevant models could help researchers detect drug-induced liver injury earlier and reduce costly setbacks.